XASX
OSL
Market cap39kUSD
Jun 02, Last price
0.00AUD
Name
Oncosil Medical Ltd
Chart & Performance
P/E
—
P/S
0.11
EPS
—
Div Yield, %
—
Shrs. gr., 5y
21.29%
Rev. gr., 5y
-32.28%
Revenues
517k
+40.51%
Net income
-12m
L+5.03%
CFO
-11m
L-4.34%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
OncoSil Medical Limited is a medical device firm dedicated to pioneering and marketing targeted radiation treatments for pancreatic cancer and distal cholangiocarcinoma on a global scale. Its flagship product, OncoSil, is a brachytherapy device specifically designed to address locally advanced, inoperable pancreatic cancer. This treatment is administered concurrently with gemcitabine-based chemotherapy. The company underwent a name change in May 2013, transitioning from NeuroDiscovery Limited to its current moniker, OncoSil Medical Limited. Established in 2005, OncoSil Medical Limited maintains its corporate headquarters in North Sydney, Australia.
Valuation
Title AUD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2024‑06 | 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | 2019‑06 | 2018‑06 | 2017‑06 | 2016‑06 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||